Well, Alnylam's back close to all time highs. Looks like the Acceleron drop was just some traders trying to manufacture price movement for a quick trade. Alnylam seems a little pricey here, but I think RNAi is flying under the radar as a major therapeutic class (obviously, it's not completely escaped the notice of the market, as 24B is a hefty valuation). It's taken a backseat in the news to newer, sexier technology like CRISPR, but seems to be reaching the slope of enlightenment part of the S-curve of technological development. Very hopeful about the next ten years, in terms of the impact this company can make in many diseases.